Luolab in Sichuan University

1. Zhang, J.; Luo, B.;  Sui, J.;  Qiu, Z.; Huang, J.;  Yang, T.; Luo, Y., IMP075 targeting ClpP for colon cancer therapy in vivo and in vitro. Biochem Pharmacol 2022, 204, 115232.

2. Zhang, J.; Qiao, W.; Luo, Y., Mitochondrial quality control proteases and their modulation for cancer therapy. Med Res Rev 2022.

3. Huang, J.; Zhang, J.;  Luo, B.;  Qiao, W.; Qiu, Z.;  Song, R.;  Dai, Z.; Sui, J.;  Xu, X.;  Ruan, S.; Li, C.;  Luo, Y.; Yang, T., Discovery of a Novel Series of Imipridone Compounds as Homo sapiens Caseinolytic Protease P Agonists with Potent Antitumor Activities In Vitro and In Vivo. J Med Chem 2022, 65 (11), 7629-7655.

4. Song, R.; Qiao, W.;  He, J.;  Huang, J.; Luo, Y.; Yang, T., Proteases and Their Modulators in Cancer Therapy:Challenges and Opportunities. J Med Chem 2021, 64 (6), 2851-287

   Yang J, Zhang L, He X, Gou X, Zong Z, Luo Y. In vitro and in vivo enhancement effect of glabridin on the antibacterial activity of colistin, against multidrug resistant Escherichia coli strains. Phytomedicine. 2024 Jul 25;130:155732. doi: 10.1016/j.phymed.2024.155732.

   Liu S, Sui J, Luo B, Zhang J, Xiang X, Yang T, Luo Y, Liu J. Discovery of 5-(Piperidin-4-yl)-1,2,4-oxadiazole Derivatives as a New Class of Human Caseinolytic Protease P Agonists for the Treatment of Hepatocellular Carcinoma. J Med Chem. 2024 Jul 11;67(13):10622-10642. doi: 10.1021/acs.jmedchem.4c00080.

   Zhou Y, Qiu Z, Dong B, Yang Y, Wang Q, Yang T, Zhang J, He Z, Zhang X, Li J, Ni X, Zeng J, Luo Y. Integrating computational and experimental approaches in discovery and validation of MmpL3 pore domain inhibitors for specific labelling of Mycobacterium tuberculosis. Int J Biol Macromol. 2024 Aug 30;279(Pt 2):135212. doi: 10.1016/j.ijbiomac.2024.135212.

   Zhang J, Qiu Z, Liu S, Huang J, Luo B, Sui J, Dai Z, Xiang X, Yang T, Luo Y. Discovery of a Novel Series of Homo sapiens Caseinolytic Protease P Agonists for Colorectal Adenocarcinoma Treatment via ATF3-Dependent Integrated Stress Response. J Med Chem. 2024 Feb 22;67(4):2812-2836. doi: 10.1021/acs.jmedchem.3c01950.

   Xiang X, Dai Z, Luo B, Zhao N, Liu S, Sui J, Huang J, Zhou Y, Gu J, Zhang J, Yang T, Bao R, Luo Y. Rational Design of a Novel Class of Human ClpP Agonists through a Ring-Opening Strategy with Enhanced Antileukemia Activity. J Med Chem. 2024 Apr 25;67(8):6769-6792. doi: 10.1021/acs.jmedchem.4c00338.

   Huang Z, Gou X, Hang X, Shi T, Yang J, Liu Y, He X, Li J, Quan K, Bi H, Luo Y. Design, Synthesis, and Biological Evaluation of 5-(5-Iodo-2-isopropyl-4-methoxyphenoxy)pyrimidine-2,4-diamine (AF-353) Derivatives as Novel DHFR Inhibitors against Staphylococcus aureus. J Med Chem. 2024 Mar 28;67(6):4757-4781. doi: 10.1021/acs.jmedchem.3c02355.

   Zhang L, Yang J, Xu X, Zhang J, Qiu Z, Ju Y, Luo B, Liu Y, Gou X, Sui J, Chen B, Wang Y, Tao T, He L, Yang T, Luo Y. Discovery and Optimization of Novel SaFabI Inhibitors as Specific Therapeutic Agents for MRSA Infection. J Med Chem. 2024 Jun 27;67(12):10096-10134. doi: 10.1021/acs.jmedchem.4c00320.

   Jiang Y, Xu X, Fan D, Liu P, Zhou M, Cheng M, Huang J, Luo Y, Guo Y, Yang T. Advancing Tumor-Targeted Chemo-Immunotherapy: Development of the CAR-M-derived Exosome-Drug Conjugate. J Med Chem. 2024 Aug 22;67(16):13959-13974. doi: 10.1021/acs.jmedchem.4c00753.

Wang Z, He L, Fan Z, Luo Y. Patenting perspective of modulators of ClpP endopeptidase: 2019-present. Expert Opin Ther Pat. 2024 Sep 16:1-12. doi: 10.1080/13543776.2024.2404233.

   Li L, Liu S, Luo Y. Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions. Eur J Med Chem. 2024 May 5;271:116394. doi: 10.1016/j.ejmech.2024.116394.

   He X, Gou X, Fan D, Yang J, Fu X, Luo Y, Yang T. Repurposing TAK875 as a novel STAT3 inhibitor for treating inflammatory bowel disease. Biochem Pharmacol. 2024 Jan;219:115957. doi: 10.1016/j.bcp.2023.115957.

   Li C, Tian X, Huang Z, Gou X, Yusuf B, Li C, Gao Y, Liu S, Wang Y, Yang T, Liu Z, Sun Q, Zhang T, Luo Y. Structure-Activity Relationship of Novel Pyrimidine Derivatives with Potent Inhibitory Activities against Mycobacterium tuberculosis. J Med Chem. 2023 Feb 23;66(4):2699-2716. doi: 10.1021/acs.jmedchem.2c01647.

   Yang Y, Zhao N, Xu X, Zhou Y, Luo B, Zhang J, Sui J, Huang J, Qiu Z, Zhang X, Zeng J, Bai L, Bao R, Luo Y. Discovery and Mechanistic Study of Novel Mycobacterium tuberculosis ClpP1P2 Inhibitors. J Med Chem. 2023 Dec 28;66(24):16597-16614. doi: 10.1021/acs.jmedchem.3c01054.

   Liu P, Jiang Y, Jiao L, Luo Y, Wang X, Yang T. Strategies for the Discovery of Oxazolidinone Antibacterial Agents: Development and Future Perspectives. J Med Chem. 2023 Oct 26;66(20):13860-13873. doi: 10.1021/acs.jmedchem.3c01040.

   Xu X, Zhang L, Yang T, Qiu Z, Bai L, Luo Y. Targeting caseinolytic protease P and its AAA1 chaperone for tuberculosis treatment. Drug Discov Today. 2023 Mar;28(3):103508. doi: 10.1016/j.drudis.2023.103508.

   He X, Gou X, Fan D, Yang J, Fu X, Luo Y, Yang T. Repurposing TAK875 as a novel STAT3 inhibitor for treating inflammatory bowel disease. Biochem Pharmacol. 2024 Jan;219:115957. doi: 10.1016/j.bcp.2023.115957.

   Zhou X, Gou K, Xu J, Jian L, Luo Y, Li C, Guan X, Qiu J, Zou J, Zhang Y, Zhong X, Zeng T, Zhou Y, Xiao Y, Yang X, Chen W, Gao P, Liu C, Zhou Y, Tao L, Liu X, Cen X, Chen Q, Sun Q, Luo Y, Zhao Y. Discovery and Optimization of Novel hDHODH Inhibitors for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2023 Nov 9;66(21):14755-14786. doi: 10.1021/acs.jmedchem.3c01365.

  Zhang J, Qiao W, Luo Y. Mitochondrial quality control proteases and their modulation for cancer therapy. Med Res Rev. 2023 Mar;43(2):399-436. doi: 10.1002/med.21929.

Yang J, Zhang L, Qiao W, Luo Y. Mycobacterium tuberculosis: Pathogenesis and therapeutic targets. MedComm (2020). 2023 Sep 4;4(5):e353. doi: 10.1002/mco2.353.

   Sui J, Qiao W, Xiang X, Luo Y. Epigenetic changes in Mycobacterium tuberculosis and its host provide potential targets or biomarkers for drug discovery and clinical diagnosis. Pharmacol Res. 2022 May;179:106195. doi: 10.1016/j.phrs.2022.106195.